Back to top
more

Evolus (EOLS)

(Delayed Data from NSDQ)

$11.50 USD

11.50
262,580

-0.20 (-1.71%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $11.48 -0.02 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (152 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Lags Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -5.85% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Nephros Inc. (NEPH) Reports Q4 Loss, Misses Revenue Estimates

Nephros Inc. (NEPH) delivered earnings and revenue surprises of -10% and 1.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Evolus, Inc. (EOLS) Reports Q3 Loss, Lags Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 18.75% and -1.08%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Evolus, Inc. (EOLS) Expected to Beat Earnings Estimates: Should You Buy?

Evolus, Inc. (EOLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -12.50% and 2.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurora Cannabis (ACB) to Post Q3 Earnings: What's in Store?

Aurora Cannabis' (ACB) sturdy consumer cannabis sales are likely to have benefited its performance in the fiscal third quarter.

Schrodinger (SDGR) to Report Q1 Earnings: What's in Store?

Schrodinger's (SDGR) first-quarter results are likely to reflect benefits from collaborations.

Why Evolus (EOLS) Might Surprise This Earnings Season

Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What's in Store for Asensus Surgical's (ASXC) Q1 Earnings?

Asensus Surgical's (ASXC) first-quarter results are likely to reflect benefits from regulatory approvals and collaboration.

Evolus, Inc. (EOLS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Evolus, Inc. (EOLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evolus, Inc. (EOLS) Reports Q4 Loss, Lags Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -231.82% and -0.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Science Applications (SAIC) 4Q Earnings?

Science Applications' (SAIC) fourth-quarter fiscal 2021 performance is likely to reflect benefits from new contract wins and acquisitions of Engility and Unisys Federal acquisition.

CuriosityStream (CURI) to Post Q4 Earnings: What's in Store?

CuriosityStream's (CURI) fourth-quarter 2020 results are expected to reflect expanding subscriber base, driven by strong factual content portfolio.

Is a Surprise Coming for Evolus (EOLS) This Earnings Season?

Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Do Options Traders Know Something About Evolus (EOLS) Stock We Don't?

Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Evolus (EOLS) Stock?

Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Evolus (EOLS) Stock?

Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.

Why Earnings Season Could Be Great for Evolus (EOLS)

Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Biocept (BIOC) to Report Q2 Earnings: What's in the Cards?

Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.

Implied Volatility Surging for Evolus (EOLS) Stock Options

Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.

Implied Volatility Surging for Evolus (EOLS) Stock Options

Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.

Kinjel Shah headshot

Allergan (AGN) Surpasses Q4 Earnings and Sales Estimates

Botox, Juvederm fillers and Vraylar drive Allergan's (AGN) fourth-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.

Kinjel Shah headshot

Allergan (AGN) Shareholders Approve Acquisition by AbbVie

Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.

What's in Store for Flexible Solutions (FSI) in Q2 Earnings?

Our proven model does not show that Flexible Solutions (FSI) is likely to beat estimates this quarter.